These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18398161)

  • 1. Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
    Punt CJ; Koopman M
    J Clin Oncol; 2008 Apr; 26(11):1907-8; author reply 1908-9. PubMed ID: 18398161
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
    Tarver K; Conibear J; Raouf S
    Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):453-4. PubMed ID: 22472457
    [No Abstract]   [Full Text] [Related]  

  • 3. [Capecitabine and irinotecan].
    Gasperoni S
    Suppl Tumori; 2004; 3(4):S107-8. PubMed ID: 15206231
    [No Abstract]   [Full Text] [Related]  

  • 4. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
    Montagnani F; Chiriatti A; Licitra S; Aliberti C; Fiorentini G
    Clin Colorectal Cancer; 2010 Oct; 9(4):243-7. PubMed ID: 20920997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
    Cartwright T; McCollum D; Boehm KA
    Am J Clin Oncol; 2010 Jun; 33(3):307-13. PubMed ID: 20375835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer.
    Gennatas C; Michalaki V; Gennatas S; Papalambros E
    Anticancer Res; 2008; 28(3B):1923-6. PubMed ID: 18630482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
    Köhne CH; De Greve J; Hartmann JT; Lang I; Vergauwe P; Becker K; Braumann D; Joosens E; Müller L; Janssens J; Bokemeyer C; Reimer P; Link H; Späth-Schwalbe E; Wilke HJ; Bleiberg H; Van Den Brande J; Debois M; Bethe U; Van Cutsem E
    Ann Oncol; 2008 May; 19(5):920-6. PubMed ID: 18065406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing.
    Goldberg RM
    Onkologie; 2010; 33(6):291-2. PubMed ID: 20523091
    [No Abstract]   [Full Text] [Related]  

  • 9. A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
    Kim KP; Kim HS; Sym SJ; Bae KS; Hong YS; Chang HM; Lee JL; Kang YK; Lee JS; Shin JG; Kim TW
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1609-17. PubMed ID: 23595344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
    Fuchs CS; Marshall J; Barrueco J
    J Clin Oncol; 2008 Feb; 26(4):689-90. PubMed ID: 18235136
    [No Abstract]   [Full Text] [Related]  

  • 11. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
    Park SH; Bang SM; Cho EK; Baek JH; Oh JH; Im SA; Park YS; Shin DB; Lee JH
    Oncology; 2004; 66(5):353-7. PubMed ID: 15331921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on capecitabine alone and in combination regimens in colorectal cancer patients.
    Silvestris N; Maiello E; De Vita F; Cinieri S; Santini D; Russo A; Tommasi S; Azzariti A; Numico G; Pisconti S; Petriella D; Lorusso V; Millaku A; Colucci G
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S46-55. PubMed ID: 21129610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
    Dahan L; Ciccolini J; Evrard A; Mbatchi L; Tibbitts J; Ries P; Norguet E; Mercier C; Iliadis A; Ouafik L; Lacarelle B; Seitz JF
    J Clin Oncol; 2012 Feb; 30(4):e41-4. PubMed ID: 22184401
    [No Abstract]   [Full Text] [Related]  

  • 14. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
    Schmoll HJ; Sargent D
    Lancet; 2007 Jul; 370(9582):105-107. PubMed ID: 17630019
    [No Abstract]   [Full Text] [Related]  

  • 15. Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.
    Clin Colorectal Cancer; 2003 Aug; 3(2):89-91. PubMed ID: 12952563
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.
    Vincenzi B; Schiavon G; Pantano F; Santini D; Tonini G
    Nat Clin Pract Oncol; 2008 Aug; 5(8):455-65. PubMed ID: 18542119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study.
    Price TJ; Townsend AR; Khattak A
    Ann Oncol; 2010 Oct; 21(10):2121; author reply 2121-2. PubMed ID: 20860991
    [No Abstract]   [Full Text] [Related]  

  • 18. Metastatic colorectal cancer: is surgery necessary?
    Schmidt C
    J Natl Cancer Inst; 2009 Aug; 101(16):1113-5. PubMed ID: 19671774
    [No Abstract]   [Full Text] [Related]  

  • 19. Capecitabine combinations in the treatment of advanced colorectal cancer.
    Fisher MD
    Clin Colorectal Cancer; 2001 Nov; 1(3):146-8. PubMed ID: 12450426
    [No Abstract]   [Full Text] [Related]  

  • 20. Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study.
    Gunnlaugsson A; Anderson H; Fernebro E; Kjellén E; Byström P; Berglund K; Ekelund M; Påhlman L; Holm T; Glimelius B; Johnsson A
    Eur J Cancer; 2009 Mar; 45(5):807-13. PubMed ID: 19110416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.